SomnoMed’s record quarter

Strong performances in the US and Europe have underpinned a record quarter for this maker of mandibular splints – and it looks like there's more to come.

SomnoMed’s share price has increased 114% since we upgraded the company in SomnoMed: A future mini-ResMed? on 5 Feb 14 (Speculative Buy – $1.33) and made the case for why substantial growth lay ahead. With revenue for the six months to 31 December increasing 18% to $14.8m, that investment case remains on track.

{{content.question}}

SMS Code Sent…

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa

Related Articles